No abstract

The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n ‫؍‬ 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive of reduced TTFT (P < .001) and overall survival (P ‫؍‬ .002). Multivariate analysis confirmed that high Ang2 was an independent prognosticator for TTFT (hazard ratio ‫؍‬ 1.739; 95% confidence interval, 1.059-2.857; P ‫؍‬ .029). Significant associations were found between high Ang2 and advanced Binet stages (P < .001), high ␤ 2 -microglobulin (P < .001), unmutated variable region of immunoglobulin heavy chain gene status (P < .001), high CD38 and -chain-associated protein kinase 70 expression (P < .001 and P ‫؍‬ .003), and intermediate/ high cytogenetic risk (P ‫؍‬ .005). Moreover, Ang2 added prognostic power to other conventional prognosticators and helped to refine prognosis among CLL subsets with both high and low vascular endothelial growth factor plasma levels. Ang2 plasma level may be a useful independent prognosticator for CLL. (Blood. 2010;116(4):584-592)

Summary The integration of molecular and clinical information to tailor treatments remains an important research challenge in chronic lymphocytic leukaemia (CLL). This study aimed to identify genomic lesions associated with a poor outcome and a higher risk of histological transformation. A mono‐institutional cohort of 147 cases was used as the test series, and a multi‐institutional cohort of 176 cases as a validation series. Genomic profiles were obtained using Affymetrix SNP 6.0. The impact of the recurrent minimal common regions (MCRs) on overall survival was evaluated by univariate analysis followed by multiple‐test correction. The independent prognostic significance was assessed by multivariate analysis. Eight MCRs showed a prognostic impact: gains at 2p25.3‐p22.3 (MYCN), 2p22.3, 2p16.2‐p14 (REL), 8q23.3‐q24.3 (MYC), losses at 8p23.1‐p21.2, 8p21.2, and of the TP53 locus. Gains at 2p and 8q and TP53 inactivation maintained prognostic significance in multivariate analysis and a hierarchical model confirmed their relevance. Gains at 2p also determined a higher risk of Richter syndrome transformation. The prediction of outcome for CLL patients might be improved by evaluating the presence of gains at 2p and 8q as novel genomic regions besides those included in the ‘standard’ fluorescence in situ hybridization panel.

No abstract

No abstract